Literature DB >> 16325821

Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis.

Michael Schoppet, Alexander M Sattler, Juergen R Schaefer, Lorenz C Hofbauer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16325821     DOI： 10.1016/j.atherosclerosis.2005.10.028

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN： 0021-9150            Impact factor:   5.162


× No keyword cloud information.
  21 in total

1.  Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults.

Authors:  Stefano Volpato; Luigi Ferrucci; Paola Secchiero; Federica Corallini; Giovanni Zuliani; Renato Fellin; Jack M Guralnik; Stefania Bandinelli; Giorgio Zauli
Journal:  Atherosclerosis       Date:  2010-11-11       Impact factor: 5.162

2.  TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe ⁻/⁻ mice.

Authors:  B A Di Bartolo; J Chan; M R Bennett; S Cartland; S Bao; B E Tuch; M M Kavurma
Journal:  Diabetologia       Date:  2011-10-01       Impact factor: 10.122

Review 3.  Pharmacological modulation of cell death in atherosclerosis: a promising approach towards plaque stabilization?

Authors:  Wim Martinet; Dorien M Schrijvers; Guido R Y De Meyer
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

4.  The relationship between circulating TRAIL and endothelial dysfunction in subclinical hypothyroidism.

Authors:  Guangda Xiang; Ling Yue; Junxia Zhang; Lin Xiang; Jing Dong
Journal:  Endocrine       Date:  2014-10-08       Impact factor: 3.633

5.  Osteoprotegerin, but Not Receptor Activator for Nuclear Factor-κB Ligand, is Associated With Subclinical Coronary Atherosclerosis in HIV-Infected Men.

Authors:  Kerunne S Ketlogetswe; Rebeccah McKibben; Lisa P Jacobson; Xuihong Li; Adrian S Dobs; Matthew Budoff; Mallory D Witt; Frank J Palella; Lawrence Kingsley; Joseph B Margolick; Wendy S Post; Todd T Brown
Journal:  J Acquir Immune Defic Syndr       Date:  2015-12-01       Impact factor: 3.731

Review 6.  Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand.

Authors:  Nor Saadah M Azahri; Mary M Kavurma
Journal:  Cell Mol Life Sci       Date:  2013-01-18       Impact factor: 9.261

Review 7.  Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily.

Authors:  Allan Flyvbjerg
Journal:  Nat Rev Endocrinol       Date:  2010-02       Impact factor: 43.330

Review 8.  Therapeutic applications of TRAIL receptor agonists in cancer and beyond.

Authors:  Gustavo P Amarante-Mendes; Thomas S Griffith
Journal:  Pharmacol Ther       Date:  2015-09-05       Impact factor: 12.310

9.  Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis.

Authors:  Emmet E McGrath; Allan Lawrie; Helen M Marriott; Paul Mercer; Simon S Cross; Nadine Arnold; Vanessa Singleton; Alfred A R Thompson; Sarah R Walmsley; Stephen A Renshaw; Ian Sabroe; Rachel C Chambers; David H Dockrell; Moira K B Whyte
Journal:  Thorax       Date:  2012-04-11       Impact factor: 9.139

10.  HDL Improves Cholesterol and Glucose Homeostasis and Reduces Atherosclerosis in Diabetes-Associated Atherosclerosis.

Authors:  Belinda A Di Bartolo; Siân P Cartland; Scott Genner; Pradeep Manuneedhi Cholan; Melissa Vellozzi; Kerry-Anne Rye; Mary M Kavurma
Journal:  J Diabetes Res       Date:  2021-05-06       Impact factor: 4.011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.